Company Profile
SELLAS Life Sciences Group, Inc. Stock Price, News & Catalysts
- Ticker:
- SLS
- Exchange:
- NASDAQ
- Sector:
- Life Science Tools
- Location:
- United States
Stock performance
13.00 USD (+1.72%)
Close
Last updated: August 17, 2026
1.55B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, SLS closed up 1.72% at $13.00. No new same-company headline was identified in the current news window.
Company overview
Late-Stage Oncology Company
SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor.
Galinpepimut-S
Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer Center. WT1 is expressed across multiple blood cancers and solid tumors, creating potential for both monotherapy and combination development.
REGAL Phase 3 Program
The Phase 3 REGAL trial evaluates GPS as maintenance therapy in acute myeloid leukemia patients who achieved complete remission after second-line salvage treatment. The event-driven study will proceed to final analysis after the prespecified 80th event.
SLS009
SLS009, also known as tambiciclib, is a selective CDK9 inhibitor designed to combine antitumor potency with reduced toxicity. SELLAS is evaluating the candidate in newly diagnosed frontline AML and preparing for potential clinical development in pancreatic cancer.
Future catalysts
- The prespecified 80th event in the Phase 3 REGAL study, triggering database lock, final analysis, and subsequent topline results.
- Topline data from the Phase 2 study of SLS009 in newly diagnosed frontline AML in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SELLAS Life Sciences Group, Inc. (SLS)?
SELLAS Life Sciences Group, Inc. (SLS) most recently closed at 13.00 USD, a +1.72% move versus the previous session.
What is the market cap of SELLAS Life Sciences Group, Inc. (SLS)?
SELLAS Life Sciences Group, Inc. currently has a market capitalization of 1.55B USD on BioPharmSignal.
What does SELLAS Life Sciences Group, Inc. do?
Late-Stage Oncology Company SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor. Galinpepimut-S Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer Center. WT1 is...
On which exchange is SLS stock listed?
SELLAS Life Sciences Group, Inc. (SLS) is associated with NASDAQ, United States, Life Science Tools.
What is tambiciclib?
SLS009 SLS009, also known as tambiciclib, is a selective CDK9 inhibitor designed to combine antitumor potency with reduced toxicity.
Which conditions is SELLAS Life Sciences Group, Inc. targeting with tambiciclib?
SELLAS Life Sciences Group, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does SELLAS Life Sciences Group, Inc. describe recent progress with tambiciclib?
The prespecified 80th event in the Phase 3 REGAL study, triggering database lock, final analysis, and subsequent topline results. Topline data from the Phase 2 study of SLS009 in newly diagnosed frontline AML in the fourth quarter of 2026.
What is Late-Stage?
Late-Stage Oncology Company SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors.